

FNS References

1. Choong E, Rudaz S, Kottelat A, Guillarme D, Veuthey JL, Eap CB. Therapeutic drug monitoring of seven psychotropic drugs and four metabolites in human plasma by HPLC-MS. *J Pharm Biomed Anal* 2009 Dec;50(5):1000-1008. https://serval.unil.ch/fr/notice/serval:BIB_A9702E4751B4
2. Choong E, Dobrinas M, Carrupt PA, Eap CB. The permeability P- glycoprotein: a focus on enantioselectivity and brain distribution. *Expert Opin Drug Metab Toxicol* 2010;6(8):953-965. https://serval.unil.ch/fr/notice/serval:BIB_B9CC1CA46639
3. Choong E, Rudaz S, Kottelat A, et al. Quantification of 4 antidepressants and a metabolite by LC-MS for therapeutic drug monitoring. *J Chromatogr B* 2011;879:1544-1550. https://serval.unil.ch/fr/notice/serval:BIB_5BEFDB40A967
4. Choong E, Bondolfi G, Etter M, et al. Psychotropic drug induced weight gain and other metabolic complications in a Swiss Psychiatric population. *J Psychiatr Res* 2012;46:540-548. https://serval.unil.ch/fr/notice/serval:BIB_B4C1EAC258AB
5. Choong E, Polari A, Kamdem RH, et al. Pharmacogenetic study on risperidone long-acting injection: influence of cytochrome P450 2D6 and Pregnane X receptor on risperidone exposure and drug-induced side-effects. *J Clin Psychopharmacol* 2013 Jun;33(3):289-298. https://serval.unil.ch/fr/notice/serval:BIB_86C0833D4954
6. Choong E, Quteineh L, Cardinaux JR, et al. Influence of CRT1 polymorphisms on body mass index and fat mass in psychiatric patients and in the general adult population. *JAMA Psychiatry* 2013 Oct 1;70(10):1011-1019. https://serval.unil.ch/fr/notice/serval:BIB_1BC1C0DFA15B
7. Quteineh L, Vandenberghe F, Saigi Morgui N, et al. Impact of HSD11B1 polymorphisms on BMI and components of the metabolic syndrome in patients receiving psychotropic treatments. *Pharmacogenet Genomics* 2015 May;25(5):246-258. https://serval.unil.ch/fr/notice/serval:BIB_361B0D4F6D36
8. Saigi-Morgui N, Vandenberghe F, Delacrétaz A, et al. Association of PCK1 with body mass Index and other metabolic features in patients with psychotropic treatments. *J Clin Psychopharmacol* 2015 Oct;35(5):544-552. https://serval.unil.ch/fr/notice/serval:BIB_65A415095D9E
9. Delacrétaz A, Preisig M, Vandenberghe F, et al. Influence of MCHR2 and MCHR2-AS1 genetic polymorphisms on body mass index in psychiatric patients and in population-based subjects with present or past atypical depression. *PLoS ONE* 2015;10(10): e0139155. https://serval.unil.ch/fr/notice/serval:BIB_200412067B84
10. Vandenberghe F, Gholam-Rezaee M, Saigi Morgui N, et al. Importance of early weight changes to predict long-term weight gain during psychotropic drug treatment. *J Clin Psychiatry* 2015 Nov;76(11):e1417-e1423. https://serval.unil.ch/fr/notice/serval:BIB_3DE3D0341247
11. Vandenberghe F, Guidi M, Choong E, et al. Genetics-based population pharmacokinetics and pharmacodynamics of risperidone in a psychiatric cohort. *Clin Pharmacokinet* 2015 Dec;54(12):1259-1272. https://serval.unil.ch/fr/notice/serval:BIB_594496D78157
12. Quteineh L, Preisig M, Rivera M, et al. Association of CRT1 polymorphisms with obesity markers in subjects from the general population with lifetime depression. *J Affect Disord* 2016 Jul 1;198:43-49. https://serval.unil.ch/fr/notice/serval:BIB_CB055B9E66F0
13. Saigi-Morgui N, Vandenberghe F, Delacrétaz A, et al. Association of genetic risk scores with body mass index in Swiss psychiatric cohorts. *Pharmacogenet Genomics* 2016 May;26(5):208-217. https://serval.unil.ch/fr/notice/serval:BIB_3012FE323A7B

14. Saigi-Morgui N, Quteineh L, Bochud PY, et al. Weighted genetic risk scores and prediction of weight gain in Solid Organ Transplant populations. PLoS ONE 2016 Oct 27; 11(10):e0164443.
https://serval.unil.ch/fr/notice/serval:BIB_ADE82491851D
15. Vandenberghe F, Saigi-Morgui N, Delacrétaz A, et al. Prediction of early weight gain during psychotropic treatment using a combinatorial model with clinical and genetic markers .
Pharmacogenet Genomics 2016 Dec;26(12):547-557.
https://serval.unil.ch/fr/notice/serval:BIB_BFD29890FF60
16. Csajka C, Crettol S, Guidi M, Eap CB. Population genetic-based pharmacokinetic modeling of methadone and relationship with the QTc interval in opioid-dependent patients. Clin Pharmacokinet 2016 Dec;55(12):1521-1523. https://serval.unil.ch/fr/notice/serval:BIB_038FD2A79BD0
17. Quteineh L, Bochud PY, Golshayan D, et al. CRT2 polymorphism as a risk factor for the incidence of metabolic syndrome traits in patients with solid organ transplantation. Pharmacogenomics J 2017 Jan;17(1):69-75. https://serval.unil.ch/fr/notice/serval:BIB_342B86B6E988
18. Delacrétaz A, Zdravovic A, Vandenberghe F, et al. Association of variants of SH2B1 and of RABEP1 with worsening of low-density lipoprotein and glucose parameters in patients treated with psychotropic drugs. Gene 2017;628:8-15. https://serval.unil.ch/fr/notice/serval:BIB_0B19BA2C151
19. Delacrétaz A, Santos Lagares P, Saigi Morgui N, et al. Influence of polygenic risk scores on lipid levels and dyslipidemia in a psychiatric population receiving weight gain-inducing psychotropic drugs.
Pharmacogenet Genomics 2017 Dec;27(12):464-472.
https://serval.unil.ch/fr/notice/serval:BIB_FB1D5A1CCA6F
20. Delacrétaz A, Vandenberghe F, Gholam-Rezaee M, et al. Early changes of blood lipid levels during psychotropic drug treatment as predictors of long-term lipid changes and of new onset dyslipidemia. J Clin Lipidol 2018 Jan- Feb;12(1):219-229. https://serval.unil.ch/fr/notice/serval:BIB_B3A7B269E9CC
21. Vandenberghe F, Najjar-Giroud A, Holzer L, Conus P, Eap CB, Ambresin AE. Second-generation antipsychotics in adolescent psychiatric patients: metabolic effects and impact of an early weight change to predict longer term weight gain. J Child Adolesc Psychopharmacol 2018 May;28(4):258-265.
https://serval.unil.ch/fr/notice/serval:BIB_E2606312F994
22. Delacrétaz A, Vandenberghe F, Glatard A, et al. Association between plasma caffeine and other methylxanthines and metabolic parameters in a psychiatric population treated with psychotropic drugs inducing metabolic disturbances. Front Psychiatry 2018 9 Nov;9(573).
https://serval.unil.ch/fr/notice/serval:BIB_EFD90D5BB70B
23. Quteineh L, Agnieszka W, Bochud PY, et al. Genetic immune and inflammatory markers associated with diabetes in solid organ transplant recipients. Am J Transplant 2019 Jan;19(1):238-246.
https://serval.unil.ch/fr/notice/serval:BIB_6D920C4CDD77
24. Saigi-Morgui N, Quteineh L, Bochud PY, et al. Genetic and clinic predictors of new onset diabetes mellitus after transplantation. Pharmacogenomics J 2019 Feb;1(53-64).
https://serval.unil.ch/fr/notice/serval:BIB_BA7F0AAB7E2E
25. Delacrétaz A, Vandenberghe F, Glatard A, et al. Lipid disturbances in adolescent treated with second-generation antipsychotics: clinical determinants of plasma lipid worsening and of new-onset hypercholesterolemia. J Clin Psychiatry 2019;80(3).
https://serval.unil.ch/fr/notice/serval:BIB_B98038AE6722
26. Ansermot N, Bochatay M, Schläpfer J, et al. Prevalence of ECG abnormalities and risk factors for QTc interval prolongation in hospitalized psychiatric patients. Ther Adv Psychopharmacol 2019 Dec 12;9:1-13.
https://serval.unil.ch/fr/notice/serval:BIB_29A9AAC54485

27. Delacrétaz A, Glatard A, Dubath C, et al. Psychotropic drug-induced genetic-epigenetic modulation of CRT1 gene is associated with early weight gain in a prospective study of psychiatric patients. *Clin Epigenetics* 2019 Dec 26;11:198. https://serval.unil.ch/fr/notice/serval:BIB_7876169F9529
28. Glatard A, Guidi M, Delacrétaz A, et al. Amisulpride: Real-world evidence of dose adaptation and effect on Prolactin concentrations and body weight gain by Pharmacokinetic/Pharmacodynamic Analyses. *Clin Pharmacokinet* 2020 Mar;59(3):371-382. https://serval.unil.ch/fr/notice/serval:BIB_750BA5D2C6D5
29. Dubath C, Delacrétaz A, Glatard A, et al. Evaluation of cardiometabolic risk in a large psychiatric cohort and comparison with a population-based sample in Switzerland. *J Clin Psychiatry* 2020 May/jun;81(3):19m12796. https://serval.unil.ch/fr/notice/serval:BIB_5B06662CFA57
30. Alameda L, Levier A, Gholam-Rezaee M, et al. Psychological trauma occurring during adolescence is associated with an increased risk of greater waist circumference in early psychosis patients treated with psychotropic medication. *PLoS ONE* 2020;15(12)(e0242569). https://serval.unil.ch/fr/notice/serval:BIB_9615E0192FAB
31. Delacrétaz A, Glatard A, Dubath C, et al. Valproate is associated with early decrease of high-density lipoprotein cholesterol levels in the psychiatric population. *Basic Clin Pharmacol Toxicol (In Press)* 2021. https://serval.unil.ch/fr/notice/serval:BIB_EBB73A5FE75D